The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Single-lesion PSMA protein expression and response to Lu-177 PSMA therapy in patients with castration-resistant prostate cancer.
 
Judith Stangl-Kremser
No Relationships to Disclose
 
Sazan Rasul
No Relationships to Disclose
 
Jeffrey J. Tosoian
Leadership - LynxDx
Stock and Other Ownership Interests - LynxDx
 
Simpa Salami
No Relationships to Disclose
 
Alexander Zaslavsky
No Relationships to Disclose
 
Aaron M. Udager
No Relationships to Disclose
 
Peter Mazal
No Relationships to Disclose
 
Renate Kain
No Relationships to Disclose
 
Eva Comperat
No Relationships to Disclose
 
Carmen Pozo Salido
No Relationships to Disclose
 
Christina Steinbach
No Relationships to Disclose
 
Melanie Hassler-Di Fratta
No Relationships to Disclose
 
Gero Kramer
No Relationships to Disclose
 
Shahrokh Shariat
Honoraria - Astellas Oncology; AstraZeneca; Bayer; BMSi; Cepheid; Ferring; Ipsen; Janssen; Lilly; MSD; Olympus; Pfizer; Pierre Fabre; Richard Wolf; Sanochemia; Sanofi; Takeda; UroGen pharma
Consulting or Advisory Role - Astellas Oncology; AstraZeneca; Bayer; BMSi; Cepheid; Ferring; Ipsen; Janssen; Lilly; MSD; Olympus; Pfizer; Pierre Fabre; Richard Wolf; Roche; Sanochemia; Sanofi; Takeda; UroGen pharma
Speakers' Bureau - Astellas Oncology; AstraZeneca; Bayer; BMSi; Cepheid; Ferring; Ipsen; Janssen; Lilly; Movember Foundation; MSD; Olympus; Pfizer; Pierre Fabre; Richard Wolf; Roche; Sanochemia; Sanofi; Takeda; UroGen pharma
 
Ganesh S. Palapattu
Stock and Other Ownership Interests - NantWorks
Consulting or Advisory Role - Janssen Scientific Affairs; SynDevRx
Research Funding - Minomic
Patents, Royalties, Other Intellectual Property - implantable nanotechnology for long term testosterone delivery functionalized fiducial marker for drug delivery